Meridian Bioscience Acquires Magellan Diagnostics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Canaccord Genuity Remains Sidelined Following Meridian Bioscience's (VIVO) Announced Magellan Diagnostics Acquisition
March 28, 2016 10:17 AM EDTCanaccord Genuity reiterated a Hold rating on Meridian Biosciences (NASDAQ: VIVO), and raised the price target to $19.00 (from $18.00), following the company's announced acquisition of Magellan Diagnostics. The acquisition marks VIVO's first material acquisition in nearly 6 years. Boston-based Magellan Diagnostics offers the only rapid (3-minute),... More
